Last reviewed · How we verify

NCT06238167

Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC

Not yet recruiting Phase 2 Last updated 2 February 2024
What this trial tests

Phase 2 trial testing Tislelizumab in Gastric Cancer in 40 participants. Not yet recruiting.

Timeline
1 April 2024
Primary endpoint
31 December 2026
31 December 2028

Quick facts

Lead sponsorFirst Affiliated Hospital of Wenzhou Medical University
PhasePhase 2
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment40
Start date1 April 2024
Primary completion31 December 2026
Estimated completion31 December 2028

Drugs / interventions tested

Conditions studied

Sponsor

First Affiliated Hospital of Wenzhou Medical University

Who can join

70 and older, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with tislelizumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or tegafur-gimeracil-oteracil potassium + oxaliplatin (SOX therapy) in PD-L1 CPS positive, elderly (≥70years old), pStage III gastric cancer (including esophagogastric junction cancer) after D2 dissection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Tislelizumab

Trials testing the same drug.

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

Other First Affiliated Hospital of Wenzhou Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06238167.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing